# Vir Biotechnology Receives FDA Fast Track Designation for Prostate Cancer Drug VIR-5500

- URL: https://stocks.freetheai.org/news/vir-biotechnology-receives-fda-fast-track-designation-for-prostate-cancer-drug-e85ad3
- Published: 2026-10-08T12:43:00Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [NASDAQ:VIR](https://stocks.freetheai.org/symbols/NASDAQ-VIR)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Vir Biotechnology, Inc. (VIR) has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its experimental prostate cancer drug, VIR-5500. The therapy is intended for patients with late-line metastatic castration-resistant prostate cancer.

The treatment, which is being co-developed with Astellas, is a PSMA-targeted T-cell engager. The FDA's Fast Track designation is designed to accelerate the development and review process for therapies addressing serious conditions with unmet medical needs. Early clinical data from Phase 1 trials showed that the drug was generally well tolerated and exhibited promising anti-tumor activity.

Currently, the drug is being evaluated in Phase 1 dose-expansion cohorts as both a standalone therapy and in combination regimens. Looking ahead, Phase 3 trials for the treatment are expected to begin in 2027. Shares of Vir Biotechnology declined slightly on the day of the announcement, trading at $11.52.

## Key points

- The FDA granted Fast Track designation to Vir Biotechnology's VIR-5500 for treating late-line metastatic castration-resistant prostate cancer.
- The experimental drug is being co-developed in partnership with Astellas.
- Early Phase 1 trial data indicated that VIR-5500 was generally well tolerated and showed anti-tumor activity.
- Phase 3 clinical trials for the prostate cancer therapy are expected to commence in 2027.

## Questions and answers

### What is VIR-5500?

VIR-5500 is an experimental PSMA-targeted T-cell engager for prostate cancer that is being co-developed by Vir Biotechnology and Astellas.

### What does the FDA Fast Track designation mean for VIR-5500?

The designation is intended to expedite the development and review of the drug to treat late-line metastatic castration-resistant prostate cancer.

### When will Phase 3 trials for VIR-5500 begin?

Phase 3 clinical trials for the drug are expected to start in 2027.